Heron Therapeutics Reports Strong Acute Care Growth, Issues Positive 2026 Revenue & Adjusted EBITDA Guidance

summarizeSummary

Heron Therapeutics announced Q4 and full-year 2025 financial results, showcasing robust growth in its Acute Care franchise and providing optimistic 2026 revenue and adjusted EBITDA guidance.

check_boxKey Events

• Strong Acute Care Franchise Growth

  The Acute Care franchise, including ZYNRELEF and APONVIE, achieved 65.1% year-over-year net revenue growth in 2025, reaching $49.6 million.

• Full-Year 2025 Revenue Achieved

  Heron Therapeutics reported $154.9 million in total net revenue for full-year 2025, representing a 7.4% increase compared to 2024.

• Positive 2026 Financial Guidance Issued

  The company issued full-year 2026 net revenue guidance of $173 to $183 million and adjusted EBITDA guidance of $10 to $20 million, indicating expected profitability on an adjusted basis.

• Key Product Milestones Achieved

  CMS approved permanent, product-specific J-Codes for both ZYNRELEF (J0668) and APONVIE (J8502), effective October 1, 2025, which is expected to streamline reimbursement and improve billing clarity.

auto_awesomeAnalysis

Heron Therapeutics announced its full financial results for Q4 and full-year 2025, following preliminary revenue figures released on January 9, 2026. The company demonstrated robust growth in its Acute Care franchise, driven by ZYNRELEF and APONVIE, which saw a 65.1% year-over-year revenue increase in 2025. Despite an overall net loss for the year, the company provided optimistic 2026 guidance, projecting significant revenue growth and a return to positive Adjusted EBITDA. Key product milestones, including the approval of permanent J-Codes for both ZYNRELEF and APONVIE, are expected to streamline reimbursement and accelerate adoption, positioning the company for continued commercial expansion.